

1 **In which patients should a custom-made acetabular implant (triflange) be**
2 **used?**

3

4 Alisagib A. Dzhavadov, Huiwu Li, Syed Shahid Noor, Alisina Shahi, Neil P.
5 Sheth, Rashid M. Tikhilov, Jorge A. Villafuerte, Huang Wei, Luigi Zagra

6

7 **Response/Recommendation:** Custom-made acetabular implants (Triflange) is an
8 option for reconstruction of acetabulum in patients with severe uncontained
9 acetabular bone loss, with or without pelvic discontinuity.

10

11 **Rationale:**

12 The increasing number of patients with severe acetabular bone loss has led to
13 the frequent use of the various options for acetabular reconstruction that includes the
14 use of custom-made acetabular implants (CMAIs) [1,2]. The purpose of this
15 umbrella review was to evaluate the outcome of patients undergoing CMAI, with
16 the intention of identifying the appropriate indications for such device.

17 Various types of studies describing the results of the use of CMAIs have been
18 published over the past two decades [3,4,5]. Using the search strategy, 187 records
19 were found. After removing 46 duplicates, the titles and abstracts of 141 studies
20 were screened. A full-text review of 15 studies was carried out. The full-text review
21 resulted in the exclusion of 12 studies. Ultimately, 2 systematic reviews and 1 meta-
22 analysis were included in the review [6,7,8]. A brief analysis of relevant studies is
23 presented here.

24 In the majority of studies the indications for the use of CMAIs was acetabular
25 defects classified as Paprosky type IIIA and IIIB or AAOS type III and IV [6,7,8].
26 A systematic review by De Martino et al. [6], including 17 studies, reported a
27 complication rate of 29 and a re-operation rate of 17.3% with the use of CMAIs. The
28 most common complication after the use of CMAIs was dislocations (11%),
29 followed by periprosthetic joint infection (PJI) (6%), nerve injury (3.8%), and

30 wound complications (2.7%). Re-operations were performed most often due to
31 dislocation (6.4%) and PJI (5.5%). Aseptic loosening of CMAIs was noted in 1.7%
32 of cases.

33 Chiarlone et al. [7], in their systematic review, pooled the results of 18 studies
34 and reported a complication rate of 29%, a re-operation rate of 19.3%, and a re-
35 revision rate of 5.2%. The main reason for re-operations was dislocation also. The
36 aseptic loosening rate of CMAIs was 2.6%. PJI and aseptic loosening constituted the
37 main reason for removal of CMAIs.

38 In a systematic review and meta-analysis, Broekhuis et al. [8] combined the
39 results of 33 studies. The rate of implant-associated infections was 24%, re-
40 operations for any reason was 15%, and implant failures of 12%. An association of
41 results with the generation of CMAIs was found, implant failure rates were higher
42 for the old generation. The results were also associated with the follow-up length
43 and study start date. Improvements in postoperative functional outcomes were noted
44 in all reviews [6,7,8].

45 Based on the available data, it appears that CMAIs have resulted in significant
46 improvement of function and satisfaction in patients with severe acetabular bone
47 loss, with or without pelvic discontinuity. Gaining experience with the use of
48 CMAIs, both on the part of surgeons and on the part of engineers involved in implant
49 development, appears to contribute to improved results.

50 However, the use of CMAIs is associated with some issues. There is a high
51 cost and wait time for the manufacturing of these prosthetic devices. In addition,
52 based on the experience of many surgeons there is usually a need for intraoperative
53 refinements to have the custom-made device fit properly. On occasions bone may
54 have to be removed or the device trimmed down to allow for an optimal fit. In recent
55 years and improvements in engineering these issues seem to have abated to some
56 extent. Nonetheless, there is a need for further research to examine the cost-
57 effectiveness of CMAIs as well as to define clearer indications for their use.

- 59 [1] Christie MC, DeBoer DK, Morrison JC, Brinson MF, Christie MJ. Bridging
60 massive acetabular defects with the triflange cup: 10- to 28-year results. *J Arthro-*
61 *plasty* 2023;38(11):2423-2428. <https://doi.org/10.1016/j.arth.2023.05.050>.
- 62 [2] Kovalenko AN, Dzhavadov AA, Shubnyakov II, Bilyk SS, Denisov AO,
63 Cherkasov MA, et al. Mid-term outcomes of using custom-made implants for
64 revision hip arthroplasty. *Traumatol Orthop Russ* 2019;25(3):37-46.
65 <https://doi.org/10.21823/2311-2905-2019-25-3-37-46>
- 66 [3] Holt GE, Dennis DA. Use of custom triflanged acetabular components in revision
67 total hip arthroplasty. *Clin Orthop Relat Res.* 2004;(429):209-14.
68 <https://doi.org/10.1097/01.blo.0000150252.19780.74>.
- 69 [4] Baauw M, van Hellemond GG, Spruit M. A Custom-made acetabular implant
70 for paprosky type 3 defects. *Orthopedics* 2017;40(1):195-198.
71 <https://doi.org/10.3928/01477447-20160902-01>.
- 72 [5] Tikhilov RM, Dzhavadov AA, Kovalenko AN, Bilyk SS, Denisov AO,
73 Shubnyakov II. Standard versus custom-made acetabular implants in revision total
74 hip arthroplasty. *J Arthroplasty* 2022;37(1):119-125.
75 <https://doi.org/10.1016/j.arth.2021.09.003>.
- 76 [6] De Martino I, Strigelli V, Cacciola G, Gu A, Bostrom MP, Sculco PK.
77 Survivorship and clinical outcomes of custom triflange acetabular components in
78 revision total hip arthroplasty: a systematic review. *J Arthroplasty*
79 2019;34(10):2511-2518. <https://doi.org/10.1016/j.arth.2019.05.032>.
- 80 [7] Chiarlone F, Zanirato A, Cavagnaro L, Alessio-Mazzola M, Felli L, Burastero
81 G. Acetabular custom-made implants for severe acetabular bone defect in revision
82 total hip arthroplasty: a systematic review of the literature. *Arch Orthop Trauma*
83 *Surg* 2020;140(3):415-424. <https://doi.org/10.1007/s00402-020-03334-5>.

84 [8] Broekhuis D, Tordoir R, Vallinga Z, Schoones J, Pijls B, Nelissen R. Custom
85 triflange acetabular components for large acetabular defect reconstruction in
86 revision total hip arthroplasty: a systematic review and meta-analysis on 1218
87 patients. *EFORT Open Rev* 2023;8(7):522-531. [https://doi.org/10.1530/EOR-22-](https://doi.org/10.1530/EOR-22-0081)
88 0081.

89